1
|
Aveiro-Róbalo TR, Paredes-González X, Recalde-Hellman C, Barboza-Molinas E, Cardozo P, Ojeda B, Ortega E, Mejia CR. Socio-academic Factors Influencing Knowledge About Organ Donation among Medical Students in Paraguay, 2018. Saudi J Kidney Dis Transpl 2021; 32:137-145. [PMID: 34145123 DOI: 10.4103/1319-2442.318515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Organ donation currently is an extremely important issue in public health. Proper information about the details of this topic is extremely important, but is not yet widespread among the public. This study was carried out with the aim to determine the level of knowledge about organ donation among medical students in Paraguay and associated socio-academic factors influencing their level of knowledge. This was an analytical cross-sectional study, based on a multicenter survey among university medical students. About 68.7% (235) of the respondents were preclinical students doing basic sciences. Two aspects were evaluated, the knowledge regarding the donation of the organs and the socio-academic factors, then both the aspects were evaluated through bivariate and multivariate analyses. There were 342 respondents with a median age of 22 years (interquartile range: 20-23 years) of which 263 (77%) were women. One hundred and eighty-eight (55%) reported not knowing the law that protects and regulates the activities of organ and tissue donation in Paraguay. In the multivariate analysis, the highest frequency of a good level of knowledge of organ donation occurred in those who were older [RPA: 1.07, 95% confidence interval (CI): 1.02-1.12, P = 0.007] and in two of the universities evaluated (both with values P <0.012). On the contrary, those who were preclinical students, in general, had a lower level of knowledge of organ donation (RPa: 0.61, 95% CI: 0.46-0.79; value P <0.001). Our findings denote relatively a poor knowledge of organ donation in some socio-academic subsets. Therefore, it is important to develop strategies to increase the knowledge about the subject, by creating opportunities by way of discussions and debates among the students at all academic levels and also by conducting academic conferences on the subject.
Collapse
Affiliation(s)
- T R Aveiro-Róbalo
- School of Medicine, Universidad del Pacifico; Scientific Society of Medical Students of the Universidad del Pacífico (SOCEM UP), Asunción; Latin American Federation of Scientific Societies of Medical Students (FELSOCEM), Itaugua, Paraguay
| | - X Paredes-González
- School of Medicine, Universidad del Pacifico; Scientific Society of Medical Students of the Universidad del Pacífico (SOCEM UP), Asunción, Paraguay
| | | | | | - P Cardozo
- School of Medicine, Universidad del Pacifico, Asunción, Paraguay
| | - B Ojeda
- School of Medicine, Universidad del Pacifico, Asunción, Paraguay
| | - E Ortega
- School of Medicine, Universidad del Pacifico, Asunción; Hospital Nacional Itaugua, Itaugua, Paraguay
| | | |
Collapse
|
2
|
Barnadas A, Muñoz M, Margelí M, Chacón JI, Cassinello J, Antolin S, Adrover E, Ramos M, Carrasco E, Jimeno MA, Ojeda B, González X, González S, Constenla M, Florián J, Miguel A, Llombart A, Lluch A, Ruiz-Borrego M, Colomer R, Del Barco S. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study. J Patient Rep Outcomes 2019; 3:72. [PMID: 31865481 PMCID: PMC6925605 DOI: 10.1186/s41687-019-0161-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2019] [Accepted: 11/15/2019] [Indexed: 11/18/2022] Open
Abstract
Background Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM. Methods Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL. Results Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0–1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity. Conclusions BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patients. Trial registration NCT03847220. Retrospectively registered on clinicaltrials.gov (February the 20th 2019).
Collapse
Affiliation(s)
- A Barnadas
- Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, C/Sant Antoni Maria Claret, 167, 08041, Barcelona, Spain. .,Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.
| | - M Muñoz
- Medical Oncology Department, Hospital Clinic i Provincial, C/ Villarroel n° 170, 08036, Barcelona, Spain
| | - M Margelí
- Medical Oncology Department, Ctra, Hospital Germans Trias i Pujol, Canyet s/n, 08916 Badalona, Barcelona, Spain
| | - J I Chacón
- Medical Oncology Department, Hospital Virgen de la Salud, Avda. Barber, n° 30, 45005, Toledo, Spain
| | - J Cassinello
- Medical Oncology Department, Hospital General de Guadalajara, C/ Donantes de Sangre, s/n, 19002, Guadalajara, Spain
| | - S Antolin
- Medical Oncology Department, Complejo Hospitalario U. A Coruña, C/ Xubias de Abaixo s/n, 15006, A Coruña, Spain
| | - E Adrover
- Medical Oncology Department, Complejo Hospitalario Universitario de Albacete, C/ Hermanos Falcó n° 37, 02006, Albacete, Spain
| | - M Ramos
- Medical Oncology Department, Centro Oncológico de Galicia, C/ Doctor Camilo Veiras s/n, 15009, A Coruña, Spain
| | - E Carrasco
- GEICAM (Spanish Breast Cancer Group), Avda. de los Pirineos n° 7, 28703 San Sebastián de los Reyes, Madrid, Spain
| | - M A Jimeno
- GEICAM (Spanish Breast Cancer Group), Avda. de los Pirineos n° 7, 28703 San Sebastián de los Reyes, Madrid, Spain
| | - B Ojeda
- Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, C/Sant Antoni Maria Claret, 167, 08041, Barcelona, Spain
| | - X González
- Medical Oncology Department, Hospital General de Catalunya, Carrer de Pedro Pons 1, 08195, Sant Cugat del Valles, Barcelona, Spain
| | - S González
- Medical Oncology Department, Hospital Mutua de Terrassa, Barcelona, Plaza del Dr. Robert n°5, 08221, Terrassa, Barcelona, Spain
| | - M Constenla
- Medical Oncology Department, Complejo Hospitalario De Pontevedra, Calle Mourente s/n, 36071, Pontevedra, Galicia, Spain
| | - J Florián
- Medical Oncology Department, Hospital Comarcal de Barbastro, Ctra. Nacional 240, s/n, 22300, Barbastro, Huesca, Spain
| | - A Miguel
- Medical Oncology Department, Hospital Althaia Manresa, C/ Dr. Joan Soler, s/n, 08243, Manresa, Barcelona, Spain
| | - A Llombart
- Medical Oncology Department, Hospital Arnau de Vilanova, Avda. Alcalde Rovira Roure, 80, 25198, Lleida, Spain
| | - A Lluch
- Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.,Hospital Clínico Universitario de Valencia, Biomedical Research Institute INCLIVA, Valencia, Spain
| | - M Ruiz-Borrego
- Medical Oncology Department, Hospital Virgen del Rocío, Avda. Manuel Siurot, s/n, 41013, Sevilla, Spain
| | - R Colomer
- Medical Oncology Department, Hospital Universitario La Princesa, C/ Diego de León n° 62, 28006, Madrid, Spain
| | - S Del Barco
- Medical Oncology Department, Hospital U. Josep Trueta, Avda. De França s/n, 17007, Gerona, Spain
| | | |
Collapse
|
3
|
Guedea F, Biete A, Ojeda B, Alonso C, Craven-Bartle J. Inflammatory Component: A Worsening Factor in Locally Advanced Breast Cancer Treated by Radiotherapy and Systemic Therapy. Tumori 2018. [DOI: 10.1177/030089169107700408] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Locally advanced and inflammatory carcinomas of the breast are two distinct entities with clear differential clinical criteria. We described a particular type of locally advanced breast cancer which, during its evolution, developed inflammatory characteristics limited to a small area of the skin. It, therefore, did not meet the common diagnostic criteria of inflammatory carcinoma. In our series, studied from December 1977 to January 1987, we treated 59 cases of locally advanced breast cancer and 105 cases of locally advanced breast cancer with an inflammatory component. The actuarial overall survival was 53.3 % at 5 years and 38.4 % at 7 years. Differences were observed when the two tumor types were compared. Specifically, locally advanced breast cancer with an inflammatory component had a worse prognosis, poorer survival and poorer disease-free rates than locally advanced breast cancer.
Collapse
Affiliation(s)
- Fernando Guedea
- Department of Radiation Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Albert Biete
- Department of Radiation Oncology, Hospital Clinic Provincial, Barcelona, Spain
| | - Belen Ojeda
- Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Carmen Alonso
- Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Jordi Craven-Bartle
- Department of Radiation Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| |
Collapse
|
4
|
Ojeda B, Salazar A, Calahorro MJ, Dueñas M, Mico JA, de Sola H, Failde I. Understanding the different relationships between mood and sleep disorders in several groups of non-oncological patients with chronic pain. Curr Med Res Opin 2018; 34:669-676. [PMID: 28945136 DOI: 10.1080/03007995.2017.1384372] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
OBJECTIVE To compare sleep dimensions in patients suffering from chronic pain of different origins, and with a group of pain-free subjects. To analyze the relationship between depression and/or anxiety and sleep disorders in musculoskeletal, neuropathic, and fibromyalgia patients. METHODS This cross-sectional study included patients diagnosed with neuropathic pain (NP) (n = 104), musculoskeletal pain (MSK) (n = 99), or fibromyalgia (FM) (n = 51), and pain free subjects (n = 72). Information about sleep dimensions (MOS-sleep), duration and intensity of pain (Visual Analog Scale), and anxiety and depression (Hospital Anxiety and Depression scale) was collected. RESULTS Of the 254 patients with chronic pain (PCP) studied, the mean pain intensity was 6.6 (SD = 1.9), with an average duration of 9 years. The scores in all sleep dimensions of the MOS-sleep were higher in CPP (more disturbances) compared to pain free patients, and differences were observed among the three groups of PCP, with FM most severely affected. Anxiety (β = 1.3), depression (β = 1.1), intensity (β = 1.7), and duration of pain (β = 0.04) were associated with more sleep problems in MSK patients. In contrast, anxiety (β = 2.5) and duration of pain (β = 0.05) were negatively related to sleep in the NP patients, and only depression (β = 1.3) affected FM patients. CONCLUSIONS The sleep pattern differs among groups of PCP in the presence or absence of mood disorders. Understanding these disorders in each specific group of PCP is fundamental, and it can contribute to improve the clinical situation of the patients and better orientating therapeutic strategies.
Collapse
Affiliation(s)
- B Ojeda
- a Preventive Medicine and Public Health Area , University of Cádiz , Spain
- b The Observatory of Pain (External Chair of Pain), University of Cádiz , Spain
- c Institute of Research and Innovation in Biomedical Sciences of the Province of Cadiz (INiBICA) , Spain
| | - A Salazar
- a Preventive Medicine and Public Health Area , University of Cádiz , Spain
- b The Observatory of Pain (External Chair of Pain), University of Cádiz , Spain
- c Institute of Research and Innovation in Biomedical Sciences of the Province of Cadiz (INiBICA) , Spain
| | - M J Calahorro
- d Medical Care Center, Andalusian Health Service , Spain
| | - M Dueñas
- b The Observatory of Pain (External Chair of Pain), University of Cádiz , Spain
- c Institute of Research and Innovation in Biomedical Sciences of the Province of Cadiz (INiBICA) , Spain
- e Faculty of Nursing 'Salus Infirmorum' , University of Cádiz , Spain
| | - J A Mico
- f Department of Neuroscience , Pharmacology and Psychiatry, CIBER of Mental Health (CIBERSAM), Institute of Health Carlos III, University of Cádiz , Spain
| | - H de Sola
- a Preventive Medicine and Public Health Area , University of Cádiz , Spain
- b The Observatory of Pain (External Chair of Pain), University of Cádiz , Spain
- c Institute of Research and Innovation in Biomedical Sciences of the Province of Cadiz (INiBICA) , Spain
| | - I Failde
- a Preventive Medicine and Public Health Area , University of Cádiz , Spain
- b The Observatory of Pain (External Chair of Pain), University of Cádiz , Spain
- c Institute of Research and Innovation in Biomedical Sciences of the Province of Cadiz (INiBICA) , Spain
| |
Collapse
|
5
|
Romero I, Leskella S, Redondo A, Gutierrez-Pecharroman A, Santaballa A, Cristobal Lana EM, Calvo E, Rosa-Rosa JM, Oaknin A, Bover I, Herrero A, Sanchez-Heras AB, Churruca CM, De Juan A, Mendiola C, Romeo M, Ojeda B, Lopez-Guerrero JA, Palacios J, Poveda A. CD8 + TILs in early stage epithelial ovarian cancer: A GEICO study. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.5543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5543 Background: The extent of tumor infiltrating lymphocytes (TILs) has emerged as a potential clinical useful biomarker in epithelial ovarian cancer (OC); however differences in TILs among OC histological types have not been extensively analysed. Methods: From a prospective early stage (I-II) GEICO registry of 1151 cases, 573 were sent for central pathology review. Complete analysis for classification of OC correctly identified 488 cases. Histological typing was performed according to morphological features and the expression of WT1, p53, p16, estrogen receptor (ER), progesterone receptor, and napsin A. The expression of mismatch repair (MMR) proteins MLH1, PMS2, MSH2 and MSH6 was performed in all tumors. The absolute number of stromal and intraepithelial CD8+ TILs per 0.6 mm2 TMA core was quantified and correlated with pathological features. Results: The series included 127 high-grade serous carcinomas (HGSC) (26%), 22 low-grade serous carcinomas (LGSOC) (4.5%), 165 endometrioid carcinomas (EC) (33.8%), 124 clear cell carcinomas (CCC) (2.4%), and 50 mucinous carcinomas (MC) (10.2%). The mean of intraepithelial CD8+ TILs was higher in HGSG (48.7) than in all other histological types (LGSG: 16.3; EC: 27.1; MC: 7.0; and CCC 10.3; p<0.0001). In the stromal component, the mean of CD8+TILs was also higher in HGSG (31.1) than in EC, MC and CCC (15.8, 8.0 and 12.7, respectively; p<0.0001). The mean of intraepithelial CD8+ TILs was significantly higher in RE-positive (71.9) than in RE-negative (34.8) HGSC ( p=0.002). In the complete series, 33 (6.6%) OCs showed absent expression of at least 1 MMR protein, and the mean of intraepithelial CD8+ TILs was significantly higher in these OCs (57.0) than in those with preserved expression of all MMR proteins (23.6; p=0.0035). MMR protein deficiency was observed in 27 (16%) ECs, and these tumours had significantly higher mean of both intraepithelial (60.4 vs. 20.7 p=0.003) and stromal CD8+ TILs (26.6 vs. 13.8, p= 0.046). No significant differences in TILs were observed among EC of different histological grades. Conclusions: The extent of CD8+TILs significantly correlates with the histological type and MMR status in OCs, being HGSCs and EC with MMR deficiency those OCs with higher CD8+TILs.
Collapse
Affiliation(s)
- Ignacio Romero
- Clinical Area of Gynecologic Oncology, Instituto Valenciano de Oncología (IVO), Valencia, Spain
| | - Susanna Leskella
- Pathology Department, Hospital Universitario Ramón y Cajal, IRyCIS, Madrid, Spain
| | | | | | - Ana Santaballa
- Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | | | - Elisa Calvo
- Hospital Universitario Virgen del Rocío, Seville, Spain
| | | | - Ana Oaknin
- Vall d’Hebron University Hospital Institute of Oncology (VHIO), Barcelona, Spain
| | | | | | | | | | - Ana De Juan
- Hospital Marques de Valdecilla, Santander, Spain
| | | | - Margarita Romeo
- Medical Oncology Department, Catalan Institute of Oncology- IDIBGi, Badalona, Spain
| | | | | | - José Palacios
- Pathology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain
| | - Andres Poveda
- Clinical Area of Gynecologic Oncology, Instituto Valenciano de Oncología (IVO), Valencia, Spain
| | | |
Collapse
|
6
|
Ojeda B, Salazar A, Dueñas M, Torres LM, Mico JA, Failde I. Assessing the Construct Validity and Internal Reliability of the Screening Tool Test Your Memory in Patients with Chronic Pain. PLoS One 2016; 11:e0154240. [PMID: 27119165 PMCID: PMC4847905 DOI: 10.1371/journal.pone.0154240] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2016] [Accepted: 04/11/2016] [Indexed: 11/18/2022] Open
Abstract
Patients with chronic pain often complain about cognitive difficulties, and since these symptoms represent an additional source of suffering and distress, evaluating the cognitive status of these patients with valid and reliable tests should be an important part of their overall assessment. Although cognitive impairment is a critical characteristic of pain, there is no specific measure designed to detect these effects in this population. The objective was to analyze the psychometric properties of the “Test Your Memory” (TYM) test in patients with chronic pain of three different origins. A cross-sectional study was carried out on 72 subjects free of pain and 254 patients suffering from different types of chronic pain: neuropathic pain (104), musculoskeletal pain (99) and fibromyalgia (51). The construct validity of the TYM was assessed using the Mini-Mental State Examination (MMSE), Hospital Anxiety and Depression Scale (HADs), Index-9 from MOS-sleep, SF-12, and through the intensity (Visual Analogical Scale) and duration of pain. An exploratory factor analysis was also performed and internal reliability was assessed using Cronbach’s alpha. After adjusting for potential confounders the TYM could distinguish between pain and pain-free patients, and it was correlated with the: MMSE (0.89, p<0.001); HAD-anxiety (-0.50, p<0.001) and HAD-depression scales (-0.52, p<0.001); MOS-sleep Index-9 (-0.49, p<0.001); and the physical (0.49, p < .001) and mental components (0.55, p < .001) of SF-12. The exploratory structure of the TYM showed an 8-factor solution that explained 53% of the variance, and Cronbach’s alpha was 0.66. The TYM is a valid and reliable screening instrument to assess cognitive function in chronic pain patients that will be of particular value in clinical situations.
Collapse
Affiliation(s)
- B. Ojeda
- Preventive Medicine and Public Health Area, The Observatory of Pain (External Chair of Pain), University of Cádiz, Cádiz, Spain
- * E-mail:
| | - A. Salazar
- Preventive Medicine and Public Health Area, The Observatory of Pain (External Chair of Pain), University of Cádiz, Cádiz, Spain
| | - M. Dueñas
- Salus Infirmorum Faculty of Nursing, University of Cádiz, Cádiz, Spain
| | - L. M. Torres
- Department of Anesthesiology-Critical Care and Pain Management, University Hospital “Puerta del Mar”, Cádiz, Spain
| | - J. A. Mico
- Department of Neuroscience, Pharmacology and Psychiatry, CIBER of Mental Health, CIBERSAM, Instituto de Salud Carlos III, University of Cádiz, Cádiz, Spain
| | - I. Failde
- Preventive Medicine and Public Health Area, The Observatory of Pain (External Chair of Pain), University of Cádiz, Cádiz, Spain
| |
Collapse
|
7
|
Tibau A, López Vilar ó L, Anguera G, Virgili A, Pérez-Olabarria M, Vázquez T, Gich I, Alonso C, Ojeda B, Ramoń y Cajal T, Murata P, Enrique L, Escuin D, Barnadas A. 266 Predictive and prognostic value of microtubule-associated protein-tau and classes I to IV b-tubulin isotypes in locally advancedbreast cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30151-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
8
|
Romero I, Churruca CM, Redondo A, Santaballa A, Calvo E, Ojeda B, Del Campo JM, Laínez N, García-Martínez E, Romeo M, Bover I, Mendiola C, Caballero C, Martinez J, Herrero A, Sánchez AB, De Juan A, Hernando Polo S, Lopez-Guerrero JA, Poveda A. Early stage ovarian cancer clinical behavior according to FIGO 2014 Staging changes with a focus on IC subtype: data from prospective GEICO registry. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.5554] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - Ana Santaballa
- Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Elisa Calvo
- Hospital Universitario Virgen del Rocío, Seville, Spain
| | | | | | - Nuria Laínez
- Complejo Hospitalario de Navarra, Pamplona, Spain
| | | | - Margarita Romeo
- Servicio de Oncologia Médica, Institut Català d'Oncologia (Hospital Germans Trias i Pujol), Badalona, Spain
| | - Isabel Bover
- GEICO and Hospital Son Llàtzer, Palma De Mallorca, Spain
| | | | | | | | | | | | - Ana De Juan
- Hospital Marques de Valdecilla, Santander, Spain
| | | | | | - Andres Poveda
- Area Clinica de Oncologia Ginecológica, Fundacion Instituto Valenciano de Oncología, Valencia, Spain
| | | |
Collapse
|
9
|
Romero I, Lopez Guerrero J, Palacios J, Ojeda B, Illueca C, Gutierrez Pecharromán A, Blanch S, Cristóbal E, Garcia Casado M, Vieites B, Ruiz Díaz I, Vera Sempere F, Pastor F, Andrada E, Culubret M, Hardisson D, Calvo E, Churruca C, Santaballa A, Poveda A. Genomic Characterization of Early Stages of Ovarian Cancer with Emphasis in Low-Grade Endometroid and Low-Grade Serous Histologies. a Study By Spanish Group for Ovarian Cancer Research (Geico). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu359.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Husain A, Wang YV, Frederiksen R, Bollag DT, Hanker LC, Ojeda B, Anttila M, Breda E, Vuylsteke P, Pujade-Lauraine E. Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab (BV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.5540] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | - Belen Ojeda
- GEICO and Hospital de la Santa Creu i Sant Pau, Department of Medical Oncology, Barcelona, Spain
| | | | | | - Peter Vuylsteke
- BGOG and Cliniques et Maternité Sainte-Elisabeth, Namur, Belgium
| | | |
Collapse
|
11
|
Ojeda B, Churruca CM, Romero I, Redondo A, Calvo E, Santaballa A, del Campo JM, Sebio A, Laínez N, Bover I, Romeo M, Caballero C, García-Martínez E, Martinez J, Herrero A, Sánchez AB, De Juan A, Hernando Polo S, Ruiz N, Poveda A. Early-stage ovarian cancer: Clinical outcome and analysis of prognostic factors—Results from a prospective registry of GEICO (Spanish Group for Ovarian Cancer Research). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.5582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Belen Ojeda
- GEICO and Hospital de la Santa Creu i Sant Pau, Department of Medical Oncology, Barcelona, Spain
| | | | - Ignacio Romero
- Area Clinica Oncologia Ginecológica. Instituto Valenciano de Oncologia, Valencia, Spain
| | | | - Elisa Calvo
- Hospital Universitario Virgen del Rocío, Seville, Spain
| | - Ana Santaballa
- Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | | | - Ana Sebio
- Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Barcelona, Spain
| | - Nuria Laínez
- Complejo Hospitalario de Navarra, Pamplona, Spain
| | - Isabel Bover
- GEICO and Son Llatzer University Hospital, Mallorca, Spain
| | - Margarita Romeo
- Servicio de Oncologia Médica, Institut Català d'Oncologia (Hostal Germans Trias i Pujol), Badalona, Spain
| | | | | | | | | | | | - Ana De Juan
- Hospital Marques de Valdecilla, Santander, Spain
| | | | - Nuria Ruiz
- Hospital Provincial de Castellón, Castellon, Spain
| | - Andres Poveda
- Area Clínica Oncología Ginecológica. Instituto Valenciano de Oncologia, Valencia, Spain
| | | |
Collapse
|
12
|
Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014; 15:640-7. [PMID: 24657003 DOI: 10.1016/s1470-2045(14)70080-4] [Citation(s) in RCA: 334] [Impact Index Per Article: 33.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
BACKGROUND In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH) trial in women with HER2-positive locally advanced or inflammatory breast cancer, neoadjuvant trastuzumab significantly improved pathological complete response rate and event-free survival. We report updated results from our primary analysis to establish the long-term benefit of trastuzumab-containing neoadjuvant therapy. METHODS We did this multicentre, open-label, randomised trial in women with HER2-positive locally advanced or inflammatory breast cancer. Participants were randomly assigned (1:1), by computer program with a minimisation technique, to receive neoadjuvant chemotherapy alone or with 1 year of trastuzumab (concurrently with neoadjuvant chemotherapy and continued after surgery). A parallel group with HER2-negative disease was included and received neoadjuvant chemotherapy alone. Our primary endpoint was event-free survival. Analysis was by intention to treat. This study is registered at www.controlled-trials.com, ISRCTN86043495. FINDINGS Between June 20, 2002, and Dec 12, 2005, we enrolled 235 patients with HER2-positive disease, of whom 118 received chemotherapy alone and 117 received chemotherapy plus trastuzumab. 99 additional patients with HER2-negative disease were included in the parallel cohort. After a median follow-up of 5.4 years (IQR 3.1-6.8) the event-free-survival benefit from the addition of trastuzumab to chemotherapy was maintained in patients with HER2-positive disease. 5 year event-free survival was 58% (95% CI 48-66) in patients in the trastuzumab group and 43% (34-52) in those in the chemotherapy group; the unadjusted hazard ratio (HR) for event-free survival between the two randomised HER2-positive treatment groups was 0.64 (95% CI 0.44-0.93; two-sided log-rank p=0.016). Event-free survival was strongly associated with pathological complete remission in patients given trastuzumab. Of the 68 patients with a pathological complete response (45 with trastuzumab and 23 with chemotherapy alone), the HR for event-free survival between those with and without trastuzumab was 0.29 (95% CI 0.11-0.78). During follow-up only four cardiovascular adverse events were regarded by the investigator to be drug-related (grade 2 lymphostasis and grade 2 lymphoedema, each in one patient in the trastuzumab group, and grade 2 thrombosis and grade 2 deep vein thrombosis, each in one patient in the chemotherapy-alone group). INTERPRETATION These results show a sustained benefit in event-free survival from trastuzumab-containing neoadjuvant therapy followed by adjuvant trastuzumab in patients with locally advanced or inflammatory breast cancer, and provide new insight into the association between pathological complete remission and long-term outcomes in HER2-positive disease.
Collapse
Affiliation(s)
| | | | | | - Ana Lluch
- Hospital Clínico Universitario de Valencia-INCLIVA Health Research Institute, University of Valencia, Valencia, Spain
| | - Sergei Tjulandin
- NN Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia
| | | | | | | | | | - Mikhail Lichinitser
- NN Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia
| | | | - Eva Ciruelos
- Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
| | - Belen Ojeda
- Hospital de la Santa Creu i Sant Pau, Department of Medical Oncology, Barcelona, Spain
| | - Mauro Mansutti
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Alla Bozhok
- NN Petrov Research Institute of Oncology, St Petersburg, Russia
| | | | | | | | | | - Jose Baselga
- Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| |
Collapse
|
13
|
Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzu D, Steinseifer J, Valagussa P, Baselga J. Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.503] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
503 Background: The monoclonal antibody trastuzumab (H) has been shown to improve event-free survival (EFS) and pathologic complete response (pCR) in patients with HER2-positive locally advanced or inflammatory breast cancer receiving neoadjuvant chemotherapy with or without one year of trastuzumab in the primary analysis of the NOAH study (Gianni L, Lancet 2010). Updated EFS and overall survival (OS) results are now presented. Methods: In this international, multicenter, open-label, randomized phase III trial patients with locally advanced or inflammatory breast cancer were randomized 1:1 to receive CT+H followed by adjuvant H versus CT alone. A parallel cohort of 99 comparable patients with HER2-negative disease was included and treated with the same chemotherapy regimen. The neoadjuvant chemotherapy regimen included doxorubicin, paclitaxel, cyclophosphamide, methotrexate and 5-fluorouracil. The primary objective was to compare EFS defined as time from randomization to disease recurrence or progression [local, regional, distant or contralateral] or death due to any cause). Results: After a median follow up of 5.4 years, the EFS benefit with trastuzumab was confirmed. Cardiac tolerability was good despite concurrent administration of trastuzumab with doxorubicin. Two patients (2%) developed reversible symptomatic congestive heart failure and are presently alive. Conclusions: Present analysis confirms the significant EFS benefit observed in the primary analysis of the NOAH study, and shows a strong trend towards improved OS with the addition of trastuzumab to chemotherapy. pCR rate may be considered as a possible primary endpoint and early indicator of benefit in future neoadjuvant studies of HER2-targeted agents. Clinical trial information: 86043495. [Table: see text]
Collapse
Affiliation(s)
| | | | | | - Alexey Manikhas
- City Clinical Oncological Dispensary, St. Petersburg, Russia
| | - Ana Lluch
- Hospital Clínico Universitario de Valencia- INCLIVA Health Research Institute, University of Valencia, Valencia, Spain
| | - Sergei Tjulandin
- Russian Oncology Research Center; N.N. Blokhin Cancer Research Center, Moscow, Russia
| | | | | | | | | | | | - Eva Ciruelos
- University Hospital 12 de Octubre, Madrid, Spain
| | - Belen Ojeda
- Hospital de la Santa Creu i Sant Pau, Departement of Medical Oncology, Barcelona, Spain
| | - Mauro Mansutti
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Alla Bozhok
- N.N. Petrov Research Institute of Oncology, St. Petersburg, Russia
| | | | | | | | - Jose Baselga
- Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
14
|
Zambetti M, Baselga J, Eiermann W, Guillem V, Semiglazov V, Lluch A, Sabadell D, Bozhok A, Byakhov MJ, Ojeda B, Mansutti M, Mariani G, Moliterni A, Cortes-Funes H, Colozza M, Pienkowski T, Magazzu D, Valagussa P, Bonadonna G, Gianni L. Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO). J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
537 Background: At the time the ECTO was designed in 1996, taxanes were only indicated for patients with metastatic breast cancer. However, paclitaxel and docetaxel were still to be tested in the adjuvant setting. In addition there was relatively scarce information on the comparative efficacy of neoadjuvant and adjuvant regimens. The ECTO trial was designed to evaluate the addition of paclitaxel to an anthracycline-based adjuvant regimen and to compare this combination with the same regimen given as primary systemic (neoadjuvant) therapy. Methods: A total of 1,355 women with operable breast cancer were randomized to one of three treatments: 1) surgery followed by adjuvant single agent doxorubicin (A) followed by CMF (arm A); 2) surgery followed by adjuvant paclitaxel plus doxorubicin (AT) followed by CMF (arm B); 3) AT followed by CMF followed by surgery (arm C). The two co-primary objectives were to assess the effects on freedom from progression (FFP) of: 1) the addition of paclitaxel to post-operative chemotherapy (arm B versus arm A); and 2) primary versus adjuvant chemotherapy (arm B versus arm C). Results: At 10 years, in the adjuvant setting FFP remained statistically significant in favor of AT followed by CMF (arm B, HR 0.77, P=0.045). Distant FFP was similarly improved but overall survival was not (HR 0.82, P=0.24). There was no significant difference in FFP when chemotherapy was given after surgery compared with the same regimen given before surgery (arm B vs arm C, HR 0.79, P=0.07). In the primary chemotherapy arm, patients who achieved a pathological complete remission (pCR) had improved distant FFP (P < 0.001) compared to patients who did not achieve pCR. When given as primary systemic therapy, the paclitaxel-containing regimen allowed breast-sparing surgery in a significant percentage of patients, which did not translate in an increased risk of ipsilateral breast recurrence compared to the risk observed in patients in the adjuvant arms. Conclusions: Incorporating paclitaxel into anthracycline-based adjuvant therapy resulted in a significantly improved FFP and DFFP.
Collapse
Affiliation(s)
| | - José Baselga
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | | | | | - Ana Lluch
- Hospital Clínico Universitario de Valencia- INCLIVA Health Research Institute, University of Valencia, Valencia, Spain
| | | | - Alla Bozhok
- N.N. Petrov Research Institute of Oncology, St. Petersburg, Russia
| | | | - Belen Ojeda
- Hospital de la Santa Creu i Sant Pau, Departement of Medical Oncology, Barcelona, Spain
| | - Mauro Mansutti
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | | | - Angela Moliterni
- Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Hernan Cortes-Funes
- Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
15
|
Font R, Espinas JA, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I, Segui MA, Margelí M, Arcusa A, Prat A, Garcia M, Borras JM. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 2012; 107:1249-56. [PMID: 22955858 PMCID: PMC3494419 DOI: 10.1038/bjc.2012.389] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
AIMS To compare different methods in order to assess adherence and persistence with oral endocrine therapy in women diagnosed with breast cancer (BC) in Catalonia. MATERIALS AND METHODS This study covered all women newly diagnosed with stage I, II or IIIa BC and positive hormone receptors at six hospitals in Catalonia (Spain) in 2004. Adherence was assessed on the basis of physician report and patient self-report using a telephone questionnaire. Persistence was measured by refill prescriptions. We used the Kappa index to compare adherence measures and logistic regression to evaluate adherence-related risk factors. RESULTS The study covered a total of 692 women. Adherence ranged from 92% (self-report) to 94.7% (physician report), depending on the measure used; persistence was 74.7% at 5 years of follow-up. Low concordance between measures was observed (Kappa range: 0.018-0.267). Patients aged 50-74 years showed higher adherence than those aged <50 years. Adherence was also associated with: adjuvant chemotherapy and sequential hormonal therapy. CONCLUSIONS Concordance between the different measures was remarkably low, indicating the need for further research. Adherence is an issue in the management of BC patients taking oral drugs, and should be assessed in clinical practice.
Collapse
Affiliation(s)
- R Font
- Catalonian Cancer Strategy Unit, Department of Health, Catalonian Regional Authority, L'Hospitalet de Llobregat, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Tibau Martorell A, Duch J, Quintana MJ, Lopez Vilaro L, Ojeda B, Alonso MC, Ramon y Cajal T, Lerma E, Moral A, Capdevila E, Pineda R, Sabate JM, Estorch M, Barnadas A. Feasibility of sentinel node biopsy in patients with locally advanced breast cancer after neoadjuvant therapy: A pilot study. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.1120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1120 Background: Sentinel lymph node biopsy (SLNB) is a widely used staging method for patients with early breast cancer. Neoadjuvant Therapy (NT) modifies the anatomical conditions in the breast and axilla, and thus reliability of SLNB after NT remains controversial. The aim of this study is to prospectively evaluate the feasibility and accuracy of this procedure in this particular group of patients. Methods: Between December 2007-2011, 69 patients (mean age 56 years) with locally advanced breast cancer (LABC) were prospectively studied. Patients were T1-4, N0-1, M0. Prior to surgery, 61 patients received chemotherapy (CT) (adryamicin/cyclophosphamide followed by docetaxel) and 8 patients endocrine therapy (ET). Thirty nine patients were initially node-negative (cN0) and 30 patients had clinical/ultrasound node-positive confirmed by cytology (cN1) at presentation. All patients were clinical and ultrasound node-negative after NT. The study contained two groups of patients: group A (validation) included the first 29, associated with an axillary lymph node dissection (ALND) after NT, in order to validate the study, and group B included the last 40, only associated with an ALND when SLNB was positive or not found. Results: Whole SLNB identification rate was 89.9%, and no significant differences were found between patients initially cN0 (92%; 36/39) and initially cN1 (87%; 26/30). Four of 7 patients in whom SLNB was not found had residual nodal metastasis after NT (3 of them were initially cN1). Sentinel lymph nodes were successfully identified in 87% (7/8) of patients after ET and in 90% (55/61) of patients after CT. There was one false negative (FN) case after CT in group A (9% of overall false negative rate, initially cN0) and there were no FN cases after ET. Positive SLNB were higher in initially cN1 group (53%; 16/30) than in initially cN0 group (18%; 7/39). Conclusions: SLNB after NT (CT or ET) is safe and feasible in patients with LABC, not only in initially cN0 but also in initially cN1. It accurately predicts the status of the axilla and avoids unnecessary ALND.
Collapse
Affiliation(s)
| | - Joan Duch
- Hospital de la Santa Creu i Sant Pau, Nuclear Medicine Department, Barcelona, Spain
| | | | - Laura Lopez Vilaro
- Hospital de la Santa Creu i Sant Pau, Pathology Department, Barcelona, Spain
| | - Belen Ojeda
- Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Barcelona, Spain
| | - M Carmen Alonso
- Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Barcelona, Spain
| | - Teresa Ramon y Cajal
- Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Barcelona, Spain
| | - Enrique Lerma
- Hospital de la Santa Creu i Sant Pau, Pathology Department, Barcelona, Spain
| | - Antonio Moral
- Hospital de la Santa Creu i Sant Pau, Department of Surgery, Barcelona, Spain
| | - Enric Capdevila
- Hospital de la Santa Creu i Sant Pau, Department of Gynecology, Barcelona, Spain
| | - Rosa Pineda
- Hospital de la Santa Creu i Sant Pau, Department of Radiology, Barcelona, Spain
| | - Josep Maria Sabate
- Hospital de la Santa Creu i Sant Pau, Department of Radiology, Barcelona, Spain
| | - Montserrat Estorch
- Hospital de la Santa Creu i Sant Pau, Nuclear Medicine Department, Barcelona, Spain
| | - Agust Barnadas
- Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Barcelona, Spain
| |
Collapse
|
17
|
Barnadas A, Tibau Martorell A, Lopez Vilaro L, Escuin D, Alonso MC, Ojeda B, Ramon y Cajal T, Fuentes MJ, Perez Garcia JI, Garcia Valdecasas B, Clotet M, Torrubia MS, Gich I, Lerma E. Topoisomerase II alpha gene status, HER2, and microtubule-associated protein tau as predictors of pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.10555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10555 Background: There is growing evidence that topoisomerase II-alpha (TOPOIIα) is a marker for anthracycline-, and microtubule-associated protein tau (MAPT) for taxane sensitivity. HER2 has been described as a marker of both anthracycline and taxane sensitivity.The goal of our study was to examine the predictive and prognostic value of TOPOIIα, MAPT and HER2 expression in breast cancer patients (pts) who received neoadjuvant chemotherapy (NAC) based on anthracycline-taxane regimens. We analyzed the relationship between these biomarkers and pathological complete response (pCR), disease-free survival (DFS) and overall survival (OS). Methods: Between November 1993-2009, 140 pts (mean age 52 years) with locally advanced breast cancer (T1-4, N0-3, M0) were retrospectively studied. The study contained 2 groups: group A included 85 pts who received NAC with an anthracycline-taxane regimen and group B included the last 55 pts who received NAC with only an anthracycline-based regimen. HER2 was tested by immunohistochemistry (IH) or FISH, TOPOIIα by CISH and MAPT by IH. Expression of these proteins was evaluated in core needle breast biopsy. Results: Overall, 12 pts (8.5%) had a pCR. TOPOIIα was amplified in 6 (4%) of the tumors. Among pts without amplification, 6 (4%) had deletion of the TOPOIIα, and 10 (7%) polysomia of chromosome 17. TOPOIIα gene aberrations (amplification, deletion, polysomia), which was present in 22 (25%) of the tumors, was a strong predictive factor for pCR (p=0.018) but showed no direct association with prognostic outcome in multivariate analysis. HER2 amplification, which was present in 16% (21) of the tumors, show no direct association with pCR, DFS or OS. Finally, differences by treatment arm or pCR in low versus high MAPT expression groups were not observed, indicating that MAPT is not a useful predictive marker for taxane-based chemotherapy. In multivariate analysis high MAPT expression was associated with longer DFS (p=0.002). Conclusions: TOPOIIα gene aberrations but not HER2 are highly predictive of pCR for anthracycline-based regimen. MAPT is not associated with response to taxanes but has a prognostic value.
Collapse
Affiliation(s)
- Agust Barnadas
- Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Barcelona, Spain
| | | | - Laura Lopez Vilaro
- Hospital de la Santa Creu i Sant Pau, Pathology Department, Barcelona, Spain
| | - Daniel Escuin
- Hospital de la Santa Creu i Sant, Medical Oncology Department, Barcelona, Spain
| | - M Carmen Alonso
- Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Barcelona, Spain
| | - Belen Ojeda
- Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Barcelona, Spain
| | - Teresa Ramon y Cajal
- Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Barcelona, Spain
| | - M Josefa Fuentes
- Hospital de la Santa Creu i Sant Pau, Radiotherapy Department, Barcelona, Spain
| | | | | | - Montserrat Clotet
- Hospital de la Santa Creu i Sant Pau, Department of Radiology, Barcelona, Spain
| | - M Sofia Torrubia
- Hospital de la Santa Creu i Sant Pau, Department of Radiology, Barcelona, Spain
| | - Ignasi Gich
- Hospital de la Santa Creu i Sant Pau, Epidemiology Department, Barcelona, Spain
| | - Enrique Lerma
- Hospital de la Santa Creu i Sant Pau, Pathology Department, Barcelona, Spain
| |
Collapse
|
18
|
Gil MJ, Bellet C, Llombart A, Ojeda B, Manso L, Mesia C, Morales S, García-Martinez H, Martínez N, Melé M, Fernández-Ortega A, Baselga J. P3-14-27: Pegylated Liposomal Doxorubicin (PLD) as Primary Treatment in Estrogen Receptor (ER) and HER2 Poor Breast Cancer and Risk of Developing Cardiotoxicity or Elderly Patients (pt). Results from the Phase II CAPRICE Study. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-14-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Combinations of doxorubicin (DX) and taxanes are considered the standard treatment in high risk breast cancer, but classical DX is not commonly used in elderly pt or in those with risk of developing cardiotoxicity. PLD (Caelyx/Doxil® is associated with less cardiotoxicity. We present a multicentric phase II trial conducted by SOLTI group. A combination of PLD and cyclophosphamide (CP) followed by paclitaxel (PTX) was tested as primary chemotherapy (CT) in pts with stage II-IIIB breast cancer with poor estrogen receptor positivity (< 50% positive nuclei) and at least one risk factor of developing cardiotoxicity. Our aim was to demonstrate a pathologic complete response (pCR) rate similar of prior DX studies without cardiac toxicity.
Method: PLD 35 mg/m2 + CP 600 mg/m2 were administered every 4 weeks (w) for 4 cycles followed by PTX 80 mg/m2 every w for 12 w. Left ventricular ejection fraction (LVEF), ECG and cardiac questionnaire were performed at baseline and 8, 16, 28, 40 w thereafter. The primary end point was pCR. Secondary endpoints included: cardiac safety, radiological response rate (RRR), breast conserving surgery (BCS) rate, toxicity and overall survival at 5 years. Results: 50 pt were included. Median age: 73 (35-84), 42 pt > 65 years old; 32 pt (64%) suffer from hypertension and 7 had prior cardiac disease. Histological grade III: 36 pts (72%); stage II/III: 24/26 pt respectively; only 13 pts (26%) were candidate for BCS at diagnosis. 46 pt (92%) underwent surgery: BCS 27 (58.6%) and mastectomy 19 (41.3%); 4 pt did not proceed to surgery due to serious adverse events. In an intent-to-treat analysis pCR rate in breast was 32% (95% CI 19.5−46.7%), 22% (95% CI 10.5−33.4%) in breast and nodes. Among triple negative pt (N=48) pCR was 33.3%. Two of seven T4d pt (28.7%) achieved pCR. No significant decrease in LVEF was seen: Mean baseline LVEF was 66.6% (52-86), 66.7 (51-88) after 16w, 62.2 (48-75) after 28w and 64.7 (50-74) after 40 w. Other toxicities: edema 10%, alopecia 10%, neutropenia 10%, stomatitis 8%, neurotoxicity 8%, skin reactions 6%, Hand-Food Syndrome 6%. Grade III-V toxicities were reported in 10 patients (20%): cardiovascular 3, diarrhea 2, rash 2, lung 2 and neutropenia 1. Three non-cancer deaths occurred: 1 sudden death in a 82 year's old pt one month after surgery, 1 due to hemorrhagic stroke > 30 days after completing CT pt with prior cerebrovascular disease, and another 84 year's old due to non-neutropenic pneumonia during CT. Conclusions: This schedule of primary chemotherapy achieves a pCR rate similar to the standard treatment and is feasible in a group of patients for whom DX was contraindicated. This strategy enables to double the BCS rate. Toxicity was acceptable in a very fragile cohort of patients.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-14-27.
Collapse
Affiliation(s)
- MJ Gil
- 1Institut Català d'Oncologia, L'Hospitalet, Barcelona; H. Vall d'Hebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de Sant Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales Messeguer, Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, Spain
| | - C Bellet
- 1Institut Català d'Oncologia, L'Hospitalet, Barcelona; H. Vall d'Hebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de Sant Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales Messeguer, Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, Spain
| | - A Llombart
- 1Institut Català d'Oncologia, L'Hospitalet, Barcelona; H. Vall d'Hebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de Sant Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales Messeguer, Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, Spain
| | - B Ojeda
- 1Institut Català d'Oncologia, L'Hospitalet, Barcelona; H. Vall d'Hebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de Sant Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales Messeguer, Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, Spain
| | - L Manso
- 1Institut Català d'Oncologia, L'Hospitalet, Barcelona; H. Vall d'Hebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de Sant Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales Messeguer, Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, Spain
| | - C Mesia
- 1Institut Català d'Oncologia, L'Hospitalet, Barcelona; H. Vall d'Hebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de Sant Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales Messeguer, Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, Spain
| | - S Morales
- 1Institut Català d'Oncologia, L'Hospitalet, Barcelona; H. Vall d'Hebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de Sant Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales Messeguer, Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, Spain
| | - H García-Martinez
- 1Institut Català d'Oncologia, L'Hospitalet, Barcelona; H. Vall d'Hebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de Sant Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales Messeguer, Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, Spain
| | - N Martínez
- 1Institut Català d'Oncologia, L'Hospitalet, Barcelona; H. Vall d'Hebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de Sant Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales Messeguer, Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, Spain
| | - M Melé
- 1Institut Català d'Oncologia, L'Hospitalet, Barcelona; H. Vall d'Hebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de Sant Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales Messeguer, Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, Spain
| | - A Fernández-Ortega
- 1Institut Català d'Oncologia, L'Hospitalet, Barcelona; H. Vall d'Hebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de Sant Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales Messeguer, Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, Spain
| | - J Baselga
- 1Institut Català d'Oncologia, L'Hospitalet, Barcelona; H. Vall d'Hebrón, Barcelona; H. Arnau de Vilanova, Lleida; H. de Sant Pau, Barcelona; H. 12 de Octubre, Madrid; H. JM Morales Messeguer, Murcia; H. Ramón y Cajal, Madrid; H. Sant Joan, Reus, Spain
| |
Collapse
|
19
|
Ojeda B, Casado A, Tibau A, Redondo A, Beltran M, Garcia-Martinez E, Santaballa A, Pardo B, Lianes P, Bover I, Garcia-Donas J, Churruca CM, Cueva JF, Sanchez-Heras AB, Gordon-Santiago MM, Arcusa Lanza A, Lopez-Rodriguez A, Caballero C, Ortega-Izquierdo ME, González-Martín A. Bevacizumab alone or with chemotherapy in highly pretreated, relapsed, epithelial ovarian cancer patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA. Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel. J Natl Cancer Inst 2010; 102:1547-1556. [DOI: 10.1093/jnci/djq362] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
21
|
Ramon Y Cajal T, Torres A, Alonso C, Fisas D, Ojeda B, Boguña I, Prat J, Baiget M, Barnadas A. Risk factors associated with the occurrence of breast cancer after bilateral salpingo-oophorectomy in high-risk women. Cancer Epidemiol 2010; 35:78-82. [PMID: 20638925 DOI: 10.1016/j.canep.2010.06.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2009] [Revised: 06/16/2010] [Accepted: 06/20/2010] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Bilateral salpingo-oophorectomy (BSO) is a common procedure for preventing breast and ovarian cancer in high-risk women. The goal of this study was to determine the incidence of subsequent breast cancer (BC) in a high-risk population and to identify clinical and epidemiological predictors of BC following BSO. MATERIALS AND METHODS One hundred and thirty-three consecutive high-risk women, tested for BRCA1 and BRCA2 mutations due to family history, underwent preventive or therapeutic BSO at one of the study hospitals. One hundred and three patients had breast tissue at risk and were considered evaluable for the event-free survival analysis. Twenty-five women harbored a deleterious mutation in BRCA1 and 25 in BRCA2 genes. RESULTS Fifteen cases of invasive BC were diagnosed with a median interval of 49 months after BSO. Multivariate analysis showed that a prior BC after 50 years of age (p=0.004), age over 50 years at the time of BSO (p=0.005), and prior replacement or contraceptive hormonal treatment (p=0.007) were significantly associated with a shorter event-free survival. CONCLUSION In conclusion, age at prior diagnosis of cancer, age at BSO and prior hormonal treatment may be predictors of breast cancer after BSO.
Collapse
|
22
|
Ciruelos EM, Cortés J, Cortés-Funes H, Mayordomo JI, Bermejo B, Ojeda B, García E, Rodríguez CA, Muñoz M, Gómez P, Manso L, Andrés R, Lluch A, Saura C, Mendiola C, Baselga J. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). Ann Oncol 2009; 21:1442-1447. [PMID: 19940004 DOI: 10.1093/annonc/mdp536] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND On the basis of clinical activity of capecitabine and gemcitabine for metastatic breast cancer, we carried out a multicenter phase II clinical trial on the combination of these two agents in advanced anthracycline-pretreated breast cancer patients. Main objectives were to assess its efficacy and safety profile. PATIENTS AND METHODS Seventy-six anthracycline-pretreated breast cancer patients were evaluated and were stratified according to previous treatment of advanced disease (group-1: not previously treated and group-2: previously treated). Study treatment consisted of gemcitabine 1000 mg/m(2), i.v., as 30 min-infusion, days 1 and 8 every 21 days, plus oral capecitabine 830 mg/m(2) b.i.d., days 1-14 every 21 days. RESULTS Overall response rate was 61% for group-1, 48.5% for group-2 and 55.2% for the whole population. Clinical benefit rate was 73% for group-1, 80% for patients in group-2 and 76% for all patients. Median time to progression was 13.0 months for group-1, 8.2 months for group-2 and 11.1 months for the whole population. Most frequent grade 3-4 observed toxic effects per patient were neutropenia (60%), asymptomatic liver toxicity (13.5%), asthenia (14%) and hand-foot syndrome (16%). Only one patient presented febrile neutropenia. No treatment-related deaths occurred. CONCLUSION Combination of gemcitabine and capecitabine is an active and safe regimen in anthracycline-pretreated breast cancer patients.
Collapse
Affiliation(s)
- E M Ciruelos
- Medical Oncology Department, University Hospital 12 de Octubre, Madrid.
| | - J Cortés
- Medical Oncology Division, Hospital Vall d'Hebron, Barcelona
| | - H Cortés-Funes
- Medical Oncology Department, University Hospital 12 de Octubre, Madrid
| | - J I Mayordomo
- Medical Oncology Division, Hospital Clínico de Zaragoza, Zaragoza
| | - B Bermejo
- Medical Oncology Division, Hospital Clínico de Valencia, Valencia
| | - B Ojeda
- Medical Oncology Division, Hospital de Sant Pau, Barcelona
| | - E García
- Medical Oncology Division, Hospital Morales Meseguer, Murcia
| | - C A Rodríguez
- Medical Oncology Division, Hospital Clínico de Salamanca, Salamanca
| | - M Muñoz
- Medical Oncology Division, Hospital Clínico de Barcelona, Barcelona, Spain
| | - P Gómez
- Medical Oncology Division, Hospital Vall d'Hebron, Barcelona
| | - L Manso
- Medical Oncology Department, University Hospital 12 de Octubre, Madrid
| | - R Andrés
- Medical Oncology Division, Hospital Clínico de Zaragoza, Zaragoza
| | - A Lluch
- Medical Oncology Division, Hospital Clínico de Valencia, Valencia
| | - C Saura
- Medical Oncology Division, Hospital Vall d'Hebron, Barcelona
| | - C Mendiola
- Medical Oncology Department, University Hospital 12 de Octubre, Madrid
| | - J Baselga
- Medical Oncology Division, Hospital Vall d'Hebron, Barcelona
| |
Collapse
|
23
|
Gonzalez-Martin A, Casado A, Blanco-Sanchez I, Bover I, Herrero A, Santaballa A, Caballero C, Churruca C, Calvo E, Ojeda B. 8025 Correlation of Topo II alpha expression and amplification with efficacy of pegylated liposomal doxorubicin in a GEICO phase II trial for platinum-resistant (PR) recurrent ovarian carcinoma (ROC). EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71547-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
24
|
Tibau A, Ojeda B, Nadal R, Pérez Altozano J, Boguña I, Artigas V, Gallardo A, Pérez C, Lopez J, Barnadas A. The predictive and prognostic value of serum CA 125 kinetics and CA 125 nadir during paclitaxel/platinum based chemotherapy in patients with advanced ovarian carcinoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16534 Background: The tumor marker CA 125 is an accurate and reliable marker for monitoring the response to treatment and detecting early relapse in epithelial ovarian cancer (EOC). The aim of this retrospective study is to analyze the predictive and prognostic value of CA 125 kinetics and the implications of the different levels of CA 125 within the normal range after chemotherapy (CT). Methods: Between 1996 and 2008, 127 patients (pts) were treated with standard CT regimen for FIGO stage IIb-IV EOC. Median age was 64 years (24–87). Tumors were classified: 70 (55%) serous, 24 (19%) poorly differentiated, 14 (11%) endometrioid and 19 (15%) clear cell carcinoma. FIGO stage: 12 (9%) II; 95 (75%) III; and 20 (16%) IV. Tumor grade: 1 (1%) G1; 11 (9%) G2; and 115 (90%) G3. Residual disease after initial surgery: 52 (41%) optimal <2cm and 39 (31%) suboptimal. After surgery, 117 (92%) of the pts received a median of 6 cycles/patient with platinum based (cisplatin or carboplatin) CT in combination with paclitaxel. Median follow-up was 31 months. 93 (73%) pts achieved levels <35 U/ml after CT. Survival analyses for disease-free survival (DFS) and overall survival (OS) used univariate (Kaplan-Meier) and multivariate (Cox) model. Results: For 127 stage IIb-IV pts, 88 (69%) relapsed and 60 (47%) died from EOC. The median DFS for 3 groups 1, 2 and 3, was 34, 20, 14 months, respectively (p < 0.0001). The median OS for 3 groups was 7.5, 3 and 3 years, respectively (p < 0.0001). Pre-CT Ca 125 (p < 0.002), and time to negativization (p < 0.043) all had a univariate prognostic value for DFS and OS. In Cox models, FIGO stage (p < 0.0001) and nadir concentration (p < 0.0001) were the most powerful prognostic factors for DFS and OS. We found no differences in DFS and OS related to time to nadir. Conclusions: Serum CA 125 kinetics during early CT has a strong predictive and prognostic relevance for patients with advanced EOC. Within normal range, the differences between CA 125 levels could add prognostic information, stratify pts according to the risk of progression and would be a useful tool when performing consolidation CT in future clinical trials. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Tibau
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital del Mar, Barcelona, Spain
| | - B. Ojeda
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital del Mar, Barcelona, Spain
| | - R. Nadal
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital del Mar, Barcelona, Spain
| | - J. Pérez Altozano
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital del Mar, Barcelona, Spain
| | - I. Boguña
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital del Mar, Barcelona, Spain
| | - V. Artigas
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital del Mar, Barcelona, Spain
| | - A. Gallardo
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital del Mar, Barcelona, Spain
| | - C. Pérez
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital del Mar, Barcelona, Spain
| | - J. Lopez
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital del Mar, Barcelona, Spain
| | - A. Barnadas
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital del Mar, Barcelona, Spain
| |
Collapse
|
25
|
Poveda A, Salazar R, del Campo JM, Mendiola C, Cassinello J, Ojeda B, Arranz JA, Oaknin A, García-Foncillas J, Rubio MJ, González Martín A. Update in the management of ovarian and cervical carcinoma. Clin Transl Oncol 2007; 9:443-51. [PMID: 17652058 DOI: 10.1007/s12094-007-0083-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Ovarian and cervical cancers are significant health problems. This article provides an update in selected management topics. Paclitaxel and platinum derivatives are the first-line treatment for patients with advanced disease. In selected patients, intraperitoneal chemotherapy has been associated with improved survival but the broad applicability of this strategy is limited by issues of toxicity and feasibility. Management of patients with recurrent disease is based on a number of factors and includes surgery in selected cases, platinum-based chemotherapy for patients with platinum-sensitive disease and other agents such as topotecan and pegylated liposomal formulation of doxorubicin for patients with platinum-resistant disease. In cervical cancer, the most significant issue/event is the demonstration of superior survival with topotecan and cisplatin compared to cisplatin alone. Finally, new agents such as epidermal growth factor receptor inhibitors and antiangiogenic agents are being currently tested in these settings.
Collapse
Affiliation(s)
- A Poveda
- Servicio de Oncología Médica, Instituto Valenciano de Oncología, Valencia, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Nadal R, Romero ML, Ojeda B, Gallardo A, Rodríguez M, Boguñà I, Gich I, Prat J, Barnadas A. Microtubule-regulatory phosphoproteins and NER system are involved in platinum and paclitaxel-based chemotherapy resistance in ovarian cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5567 Background: The treatment of ovarian cancer is hindered by intrinsic resistance to platinum and paclitaxel-based chemotherapy (CT). Nucleotide excision repair system plays a central role in DNA repair and is related with resistance to platinum compounds. Excision repair cross-complementation 1 (ERCC1) and 3 (ERCC3) genes confer a differential sensitivity to CT. OP18/stathmin and mDIA are involved in regulation of microtubules dynamics and may represent a mechanism of resistance to paclitaxel. Both mechanisms have been recently investigated in ovarian cancer (OC). Methods: Formalin and paraffin-embedded tissues obtained from 33 patients with advanced OC were retrospectively collected to investigate ERCC1, ERCC3, OP18, and mDIA mRNA levels by quantitative RT- PCR. All patients received a median of 6 cycles platinum based CT in combination with taxanes. Median age was 62 years. Tumors were classified: 52% serous, 9% endometrioid, 27% clear cell, and 12% poorly differentiated carcinomas. FIGO stage: 4 (12%) stage II, 19 (58%) stage III, and 10 (30%) stage IV. 12 chemoresistant tumors (time to recurrence (TTR) < 6 months) and 21 chemosensitive tumors (TTR = 6 months) were analyzed. Median follow-up was 31 months. Results: An increase in mRNA levels was consistently observed in the chemoresistent group: 1.9-fold increased in ERCC1 and 1.6-fold increased in ERCC3. Both genes exhibited comparable expression levels. Statistically significant differences on ERCC1 and ERCC3 mRNA levels were encountered when chemoresistant and chemosensitive tumors were compared (p=0.01 and p= 0.03, respectively). Statistically differences on OP18 mRNA levels were found when chemoresistant and chemosensitive tumors were compared (p=0.05). No differences in mDIA mRNA levels were encountered. Conclusions: Our results suggest that determination of ERCC1-ERCC3 before chemotherapy is potentially useful to predict the effectiveness of platinum-based therapy. Microtubule drug resistance in OC may be associated with altered OP18/stathmin expression. Novel treatment approaches based on molecular markers could be useful predictors of response and could identify targets for therapeutic strategies. Further studies are required. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. Nadal
- Hospital De Sant Pau, Barcelona, Spain
| | | | - B. Ojeda
- Hospital De Sant Pau, Barcelona, Spain
| | | | | | - I. Boguñà
- Hospital De Sant Pau, Barcelona, Spain
| | - I. Gich
- Hospital De Sant Pau, Barcelona, Spain
| | - J. Prat
- Hospital De Sant Pau, Barcelona, Spain
| | | |
Collapse
|
27
|
Ciruelos EM, Baselga J, Cortes-Funes H, Lluch A, Mayordomo JI, Ojeda B, Gonzalez E, Muñoz M, Rodriguez C, Cortes J. Multicentric phase II trial of gemcitabine plus capecitabine combination in the treatment of previously anthracycline(An)-treated metastatic breast cancer (MBC): SOLTI 0301 study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1051 Background: Based on clinical activity of capecitabine(C) and gemcitabine (G) on the treatment of MBC, we performed a multicentric phase II trial of the combination to test its efficacy and safety profile. Methods: Sample size of 72 evaluable MBC patients (pts) previously An-treated (neoadjuvant 8%, adjuvant 69%, advanced 30%). Median age: 59 years (35–76 years). Estrogen Receptor positive: 47 (65%). HER2 overexpression: 16 (22%). Prior hormonal/trastuzumab allowed. Soft tissue/ganglionar/pleural/bone disease: 19 (26%); visceral metastasis: 53(74%). Stratification: previous chemotherapy (CT) for advanced disease (none: group 1; any: group 2). Study treatment: oral bid C 1,660 mg/m2/day (d) (d1–14) + iv G 1,000 mg/m2/d (d1&8). Cycles repeated every 3 weeks. RECIST/NCI-CTC 2.0 criteria. Primary end point: Objective Response Rate. Results: Response Rates and Clinical Benefit (CB) are detailed in the table . Median follow-up 7.2 months (m) (0.2–18.4). Median time to progression 11.2 m: group 1, 12 m (95%CI: 6.4–14.5); group 2, 8.9 m (95%CI: 6.9–14).Total and median administered cycles/pt: 479 and 8. Delayed cycles: 103(21.5%): 27% due to hematological toxicity, 11% due to non-hematological toxicity, 62% due to other causes. C dose reduced in 27 cycles (5.6%), 12 of them due to non- hematological toxicity. G dose reduced in 169 cycles (35%), mostly on day 8, and due to hematological toxicity (80% of reduced cycles). Grade 3–4 neutropenia: 32 pts (56%), 1 case of febrile neutropenia. Grade 3–4 non-hematological toxicities: asthenia 8 pts (14%), hand- foot syndrome 6 pts (10.5%), mucositis 3 pts (5%), diarrhea 2 pts (3.5%). Conclusions: Combination of C+G in the treatment of previously anthracycline-treated MBC is safe and active, with a manageable toxicity profile and a good clinical activity. [Table: see text] No significant financial relationships to disclose.
Collapse
|
28
|
Colomer R, Llombart-Cussac A, Tusquets I, Rifà J, Mayordomo JI, Ojeda B, Ciruelos E, Hornedo J, Vicente D, Cortés-Funes H. Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain. Clin Transl Oncol 2006; 8:896-902. [PMID: 17169763 DOI: 10.1007/s12094-006-0153-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Purpose. To assess the toxicity and efficacy of biweekly gemcitabine plus vinorelbine in first-line advanced breast cancer, and to establish whether circulating HER2 ECD levels correlate with the efficacy of the combination. Patients and methods. 52 patients were treated with gemcitabine 2500 mg/m(2) plus vinorelbine 30 mg/m(2), both on day 1 of 14-day cycles, for a maximum of 10 cycles. Baseline serum levels of HER2 ECD were assessed with an ELISA. Results. All patients were evaluable for toxicity, and 50 for efficacy. Overall toxicity was moderate. Grade 3 neutropenia occurred in 35% of patients and grade 4 in 19%. Other grade 3 toxicities were observed in less than 6%. There was one episode of febrile neutropenia, and one death after cycle three. Overall response rate was 52% (95% CI: 38% to 66%), with 2 patients achieving a CR (4%). Response rate did not correlate with HER2 ECD, with 50% of HER2 ECD positive patients responding, vs 48.5% of the HER2 ECD negative. Median overall survival was 24.6 months. Conclusion. Gemcitabine plus vinorelbine, given as an every-two-week schedule, is an active regimen in advanced breast carcinoma. This combination can be an option when anthracyclines and taxanes are not preferred. HER2 ECD has no predictive value in this non-taxane combination.
Collapse
Affiliation(s)
- R Colomer
- Institut Catala d'Oncologia, Girona, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Ojeda B, Gonzaléz-Martín A, Mellado B, Bover I, Fabregat X, Rubio MJ, Alonso L, Lianes P, Churruca C, Poveda A. Prolonged infusion of gemcitabine in patients with platinum resistant or refractory recurrent ovarian carcinoma: A phase II study Of GEICO (Spanish Group for investigation on ovarian cancer). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- B. Ojeda
- Hosp de Sant Pau, Barcelona, Spain; Hosp Ramón y Cajal, Madrid, Spain; Hosp Clinic I Provincial de Barcelona, Barcelona, Spain; Hosp de Sont Llatzer, Palma de Mallorca, Spain; Hosp del Mar, Barcelona, Spain; Hosp Reina Sofía, Córdoba, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp de Mataró, Barcelona, Spain; Hosp de Donostia, San Sebastián, Spain; IVO (Instituto Valenciano de Oncología), Valencia, Spain
| | - A. Gonzaléz-Martín
- Hosp de Sant Pau, Barcelona, Spain; Hosp Ramón y Cajal, Madrid, Spain; Hosp Clinic I Provincial de Barcelona, Barcelona, Spain; Hosp de Sont Llatzer, Palma de Mallorca, Spain; Hosp del Mar, Barcelona, Spain; Hosp Reina Sofía, Córdoba, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp de Mataró, Barcelona, Spain; Hosp de Donostia, San Sebastián, Spain; IVO (Instituto Valenciano de Oncología), Valencia, Spain
| | - B. Mellado
- Hosp de Sant Pau, Barcelona, Spain; Hosp Ramón y Cajal, Madrid, Spain; Hosp Clinic I Provincial de Barcelona, Barcelona, Spain; Hosp de Sont Llatzer, Palma de Mallorca, Spain; Hosp del Mar, Barcelona, Spain; Hosp Reina Sofía, Córdoba, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp de Mataró, Barcelona, Spain; Hosp de Donostia, San Sebastián, Spain; IVO (Instituto Valenciano de Oncología), Valencia, Spain
| | - I. Bover
- Hosp de Sant Pau, Barcelona, Spain; Hosp Ramón y Cajal, Madrid, Spain; Hosp Clinic I Provincial de Barcelona, Barcelona, Spain; Hosp de Sont Llatzer, Palma de Mallorca, Spain; Hosp del Mar, Barcelona, Spain; Hosp Reina Sofía, Córdoba, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp de Mataró, Barcelona, Spain; Hosp de Donostia, San Sebastián, Spain; IVO (Instituto Valenciano de Oncología), Valencia, Spain
| | - X. Fabregat
- Hosp de Sant Pau, Barcelona, Spain; Hosp Ramón y Cajal, Madrid, Spain; Hosp Clinic I Provincial de Barcelona, Barcelona, Spain; Hosp de Sont Llatzer, Palma de Mallorca, Spain; Hosp del Mar, Barcelona, Spain; Hosp Reina Sofía, Córdoba, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp de Mataró, Barcelona, Spain; Hosp de Donostia, San Sebastián, Spain; IVO (Instituto Valenciano de Oncología), Valencia, Spain
| | - M. J. Rubio
- Hosp de Sant Pau, Barcelona, Spain; Hosp Ramón y Cajal, Madrid, Spain; Hosp Clinic I Provincial de Barcelona, Barcelona, Spain; Hosp de Sont Llatzer, Palma de Mallorca, Spain; Hosp del Mar, Barcelona, Spain; Hosp Reina Sofía, Córdoba, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp de Mataró, Barcelona, Spain; Hosp de Donostia, San Sebastián, Spain; IVO (Instituto Valenciano de Oncología), Valencia, Spain
| | - L. Alonso
- Hosp de Sant Pau, Barcelona, Spain; Hosp Ramón y Cajal, Madrid, Spain; Hosp Clinic I Provincial de Barcelona, Barcelona, Spain; Hosp de Sont Llatzer, Palma de Mallorca, Spain; Hosp del Mar, Barcelona, Spain; Hosp Reina Sofía, Córdoba, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp de Mataró, Barcelona, Spain; Hosp de Donostia, San Sebastián, Spain; IVO (Instituto Valenciano de Oncología), Valencia, Spain
| | - P. Lianes
- Hosp de Sant Pau, Barcelona, Spain; Hosp Ramón y Cajal, Madrid, Spain; Hosp Clinic I Provincial de Barcelona, Barcelona, Spain; Hosp de Sont Llatzer, Palma de Mallorca, Spain; Hosp del Mar, Barcelona, Spain; Hosp Reina Sofía, Córdoba, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp de Mataró, Barcelona, Spain; Hosp de Donostia, San Sebastián, Spain; IVO (Instituto Valenciano de Oncología), Valencia, Spain
| | - C. Churruca
- Hosp de Sant Pau, Barcelona, Spain; Hosp Ramón y Cajal, Madrid, Spain; Hosp Clinic I Provincial de Barcelona, Barcelona, Spain; Hosp de Sont Llatzer, Palma de Mallorca, Spain; Hosp del Mar, Barcelona, Spain; Hosp Reina Sofía, Córdoba, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp de Mataró, Barcelona, Spain; Hosp de Donostia, San Sebastián, Spain; IVO (Instituto Valenciano de Oncología), Valencia, Spain
| | - A. Poveda
- Hosp de Sant Pau, Barcelona, Spain; Hosp Ramón y Cajal, Madrid, Spain; Hosp Clinic I Provincial de Barcelona, Barcelona, Spain; Hosp de Sont Llatzer, Palma de Mallorca, Spain; Hosp del Mar, Barcelona, Spain; Hosp Reina Sofía, Córdoba, Spain; Hosp Virgen de la Victoria, Málaga, Spain; Hosp de Mataró, Barcelona, Spain; Hosp de Donostia, San Sebastián, Spain; IVO (Instituto Valenciano de Oncología), Valencia, Spain
| |
Collapse
|
30
|
González-Martín AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda B, Balañá C, Martínez E, Herrero A, Pardo B, Adrover E, Rifá J, Godes MJ, Moyano A, Cervantes A. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 2005; 16:749-55. [PMID: 15817604 DOI: 10.1093/annonc/mdi147] [Citation(s) in RCA: 98] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The aim of this study was to determine whether the response rate for the paclitaxel-carboplatin combination is superior to carboplatin alone in the treatment of patients with platinum-sensitive recurrent ovarian carcinoma. PATIENTS AND METHODS Patients with recurrent ovarian carcinoma, 6 months after treatment with a platinum-based regimen and with no more than two previous chemotherapy lines, were randomized to receive carboplatin area under the curve (AUC) 5 (arm A) or paclitaxel 175 mg/m(2) + carboplatin AUC 5 (arm B). The primary end point was objective response, following a 'pick up the winner' design. Secondary end points included time to progression (TTP), overall survival, tolerability and quality of life (QoL). RESULTS Eighty-one patients were randomized and included in the intention-to-treat analysis. The response rate in arm B was 75.6% [26.8% complete response (CR) + 48.8% partial response (PR)] [95% confidence interval (CI) 59.7% to 87.6%] and 50% in arm A (20% CR + 30% PR) (95% CI 33.8% to 66.2%). No significant differences were observed in grade 3-4 hematological toxicity. Conversely, mucositis, myalgia/arthralgia and peripheral neurophaty were more frequent in arm B. Median TTP was 49.1 weeks in arm B (95% CI 36.9-61.3) and 33.7 weeks in arm A (95% CI 25.8-41.5). No significant differences were found in the QoL analysis. CONCLUSIONS Paclitaxel-carboplatin combination is a tolerable regimen with a higher response rate than carboplatin monotherapy in platinum-sensitive recurrent ovarian carcinoma.
Collapse
Affiliation(s)
- A J González-Martín
- Medical Oncology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Macarulla T, Prado Venegas M, León X, López Pousa A, Quer M, Orús C, Guardeño R, Nadal R, Ojeda B, Gallego O. Smoke and alcohol consumption as a risk factors in the development of second primary neoplasms (SPN) in head & neck cancer (HNC) patients. A case-control study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - X. León
- Hospital Sant Pau, Barcelona, Spain
| | | | - M. Quer
- Hospital Sant Pau, Barcelona, Spain
| | - C. Orús
- Hospital Sant Pau, Barcelona, Spain
| | | | - R. Nadal
- Hospital Sant Pau, Barcelona, Spain
| | - B. Ojeda
- Hospital Sant Pau, Barcelona, Spain
| | | |
Collapse
|
32
|
Colomer R, Llombart-Cussac A, Lluch A, Barnadas A, Ojeda B, Carañana V, Fernández Y, García-Conde J, Alonso S, Montero S, Hornedo J, Guillem V. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol 2004; 15:201-6. [PMID: 14760109 DOI: 10.1093/annonc/mdh048] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND We wanted to assess the toxicity and efficacy of paclitaxel plus gemcitabine in advanced breast cancer and to confirm whether circulating HER2 extracellular domain (ECD) correlates with treatment response. PATIENTS AND METHODS Forty-three patients received paclitaxel 150 mg/m2 followed by gemcitabine 2500 mg/m2, both on day 1 of 14-day cycles, with a maximum of eight cycles. Serum levels of HER2 ECD were assessed by ELISA. RESULTS All patients were evaluable for toxicity and 42 for efficacy. Overall toxicity was low. Grade 3 neutropenia occurred in 12% of patients and grade 4 in 17%, and other grade 3 toxicities in <5%. One patient had an allergic infusion reaction. Overall response rate was 71% [95% confidence interval (CI) 62% to 81%], with 11 patients achieving a complete response (26%). With a median follow-up of 26 months, the median time to progression was 16.6 months. Response rate correlated significantly with HER2 ECD, with 42% of HER2 ECD-positive patients responding versus 83% of HER2 ECD-negative patients (P = 0.02). Furthermore, response duration was shorter in patients with positive HER2 ECD levels (7.9 versus 14.4 months; P = 0.04). CONCLUSIONS Paclitaxel plus gemcitabine given as an every 2-weeks schedule is a well tolerated and active regimen in advanced breast carcinoma. This is an attractive combination to use when anthracyclines are not indicated, such as in HER2 positive cases that receive trastuzumab. In addition, elevated levels of HER2 ECD adversely affect the efficacy of treatment.
Collapse
Affiliation(s)
- R Colomer
- Institut Català d'Oncologia, Hospital Dr Josep Trueta, Girona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Ojeda B, de Sande LM, Casado A, Merino P, Casado MA. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Br J Cancer 2003; 89:1002-7. [PMID: 12966416 PMCID: PMC2376947 DOI: 10.1038/sj.bjc.6601228] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
The study consisted of a cost-minimisation analysis since the findings from a multicentre randomised phase III trial showed that pegylated liposomal doxorubicin hydrochloride was at least as efficacious as topotecan. An economic model from the Spanish hospitals perspective was constructed to compare the costs derived from the treatment using both drugs in patients with recurrent epithelial ovarian cancer who failed a first-line platinum-containing regimen. The cost evaluation included direct medical costs: drug, drug administration and costs of managing adverse events. Estimation of resources used in managing adverse events was made retrospectively through an expert panel. Results obtained per patient were: cost of drug and administration, 8647.70 euros for pegylated liposomal doxorubicin hydrochloride and 8519.94 euros for topotecan, while cost of managing adverse events was 967.02 euros in the pegylated liposomal doxorubicin hydrochloride arm and 3304.75 euros for topotecan. The total cost per patient was therefore estimated to be 9614.72 euros for pegylated liposomal doxorubicin hydrochloride and 11 824.69 euros for topotecan, showing that pegylated liposomal doxorubicin hydrochloride produces a cost saving of 2209.97 euros per patient in comparison to topotecan. Sensitivity analyses verified the robustness of the results. These findings suggest that pegylated liposomal doxorubicin hydrochloride is an efficient therapy and can be used as a cost-saving option for treatment of patients with recurrent epithelial ovarian cancer who have failed a first-line platinum-containing regimen.
Collapse
Affiliation(s)
- B Ojeda
- Department of Medical Oncology, Hospital de la Santa Cruz y San Pablo, Avgda. Sant Antoni María Claret 167, 08025 Barcelona, Spain.
| | | | | | | | | |
Collapse
|
34
|
Hornedo J, Solá C, Solano C, López JJ, Alonso S, Lluch A, Ojeda B, Garcia-Conde J, Cortés-Funes H. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant 2002; 29:737-43. [PMID: 12040470 DOI: 10.1038/sj.bmt.1703539] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2001] [Accepted: 02/12/2002] [Indexed: 11/09/2022]
Abstract
The administration of G-CSF post transplant has been shown to accelerate the time to neutrophil engraftment. However, this does not necessarily translate into a meaningful clinical benefit to the patient. This randomized study was designed to determine the role of G-CSF following transplantation in patients with breast cancer (BC). A total of 241 evaluable patients with BC were included. There were 200 patients with high-risk BC, and 41 had disseminated BC in complete remission. All patients received conventional dose chemotherapy prior to transplantation. Patients were mobilized with G-CSF, received the STAMP V regimen, were transplanted with > or = 2.5 x 10(6) of CD34(+) cells/kg and were then randomized to receive 5 microg/kg of G-CSF starting on the day of infusion (arm A), five days later (arm B), or no G-CSF (arm C). The need for transfusion support, infectious complications and length of hospitalization were the variables chosen to demonstrate clinical benefit. Patients receiving G-CSF reached 500 and 1000 neutrophils significantly faster (P = 0.001) than patients with no G-CSF. This translated into a significantly (P < 0.05) shorter hospitalization time for patients receiving G-CSF. Arm C was closed and, after recruiting 110 patients in arm A, and 106 in arm B, the significant difference in neutrophil recovery persisted with no difference in the time of hospitalization between arms A and B. Therefore, G-CSF significantly accelerates the time to neutrophil engraftment. This translates into a shorter time of hospitalization. There is no difference in this variable regarding the time of administering the G-CSF: day 0 vs day +5. Therefore, G-CSF on day +5 should be the standard in this setting.
Collapse
Affiliation(s)
- J Hornedo
- Department of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Climent MA, Seguí MA, Peiró G, Molina R, Lerma E, Ojeda B, López-López JJ, Alonso C. Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment. Breast 2001; 10:67-77. [PMID: 14965564 DOI: 10.1054/brst.2000.0225] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
HER-2/neu and p53 expression, conventional clinical and pathologic prognostic factors, were evaluated in a retrospective series of 283 node-positive breast cancer patients. Overexpression was determined by immunohistochemistry in formalin-fixed paraffin-embedded tissue blocks. Twenty one percent were HER-2/neu positive and 40% p53 positive. HER-2/neu expression was related to axillary lymph node metastasis (P=0.014), inflammatory infiltrates (P=0.004), and the absence of oestrogen (ER) (P=0.0026) and progesterone (P=0.01) receptors (PR). p53 expression was related to lymph node involvement (P=0.03), necrosis (P=0.036), absence of ER (P=0.028) and PR (P=0.065). p53 was not associated with outcome. HER-2/neu was an unfavourable prognostic factor for disease-free (DFS) (P=0.05) and overall survival (OS) (P=0.02) in univariate analysis. Multivariate analysis showed that the number of involved axillary nodes (P<0.00001), age (P=0.004), grade (P=0.04), and PR (P=0.04) were independent predictors for OS. ER-positive patients treated with adjuvant tamoxifen had shorter DFS and OS when they were HER-2/neu positive.
Collapse
Affiliation(s)
- M A Climent
- Instituto Valenciano de Oncología, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Lluch A, Ojeda B, Colomer R, Barnadas A, Massuti B, Casado A, Angeles C, Maroto P. Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy. Cancer 2000; 89:2169-75. [PMID: 11147586 DOI: 10.1002/1097-0142(20001201)89:11<2169::aid-cncr4>3.0.co;2-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND The authors undertook a Phase II multicenter trial to assess the efficacy and toxicity of doxorubicin and paclitaxel in combination in the treatment of patients with metastatic breast carcinoma. METHODS Doxorubicin (50 mg/m2, bolus) followed by paclitaxel (175 mg/m2 over 3 hours) was administered every 21 days (for a maximum of 10 cycles) as first-line chemotherapy in 77 patients, 41 of whom had received prior adjuvant chemotherapy. Monitoring of cardiac function (left ventricular ejection fraction[LVEF]) and total doxorubicin cumulative dose were included in the study protocol. RESULTS Grade 4 hematologic toxicities were neutropenia (58%) and thrombocytopenia (4%). Neutropenic fever occurred in 9% of patients. Nonhematologic Grade 4 toxicity was limited to mucositis (3%). Grade 3 toxicities were neutropenia (35%), anemia (3%), alopecia (93%), peripheral neuropathy (18%), arthralgia/myalgia (8%), and mucositis (9%). No clinical cardiotoxicity (Grades 3 or 4) occurred. Treatment was discontinued in 5 patients who showed a decrease of LVEF of greater than 15% during therapy. Of 73 patients assessable for response, 15 were complete response, 42 partial response, 15 stable disease, and 1 disease progression; overall response rate being 78% (95% confidence interval [CI], 67-87). Median follow-up was 22 months. Median time to progression (TP) was 10 months (95% CI, 7-12). Time to progression was poorer in cases with adjuvant anthracycline therapy than those without adjuvant chemotherapy (7 vs. 12.3 months; P = 0.022), but TP in patients with adjuvant chemotherapy not containing anthracyclines was not different from the cases without adjuvant chemotherapy (8.6 months). Estimated 2-year survival was 51% (standard error, 7%). CONCLUSIONS Our results confirm that the combination of paclitaxel and doxorubicin is effective in the treatment of metastatic breast carcinoma, and that it is well tolerated. No clinical cardiotoxicity was observed on close cardiac monitoring, and prior adjuvant anthracycline treatment compromised its efficacy.
Collapse
Affiliation(s)
- A Lluch
- Hospital Clínico, Valencia, Spain
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massutí B, Cortés-Funes H, Lloveras B. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000; 6:2356-62. [PMID: 10873087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
To test the hypothesis of an association between HER2 and chemotherapy resistance, we performed a prospective assessment of the predictive value of the circulating HER2 extracellular domain (ECD) in patients with advanced breast carcinoma in the setting of a multicenter Phase II trial using paclitaxel and doxorubicin. Serum samples were collected from 58 patients with metastatic breast carcinoma before first-line chemotherapy for advanced disease, and the levels of circulating HER2 ECD were measured using an enzyme immunoassay. Immunohistochemistry with anti-HER2 monoclonal antibody CB11 was used to assess the overexpression of HER2 in the primary tumors. When 450 fmol/ml was used as a cutoff, 24 cases (41%) had elevated HER2 ECD levels. Elevated levels of circulating HER2 ECD were associated with the expression of HER2 in the primary tumor tissue and with the metastatic tumor burden (evaluated with the marker CA 15-3; P = 0.032 and P = 0.002, respectively) but not with variables such as menopausal status, stage at diagnosis, previous adjuvant therapy, or the number of metastatic sites. The levels of circulating HER2 ECD correlated inversely with the response to treatment. The probability of obtaining a complete response to chemotherapy was significantly lower (P = 0.021) in patients with elevated HER2 ECD levels (0%; 95% confidence interval, 0-13%) compared with patients with nonelevated HER2 (26%; 95% confidence interval, 12-45%). In addition, the duration of clinical response was significantly shorter in patients with elevated HER2 ECD, compared with the cases with nonelevated HER2 (7.5 versus 11 months; P = 0.035). In conclusion, elevated levels of circulating HER2 ECD in patients with metastatic breast cancer correlate with reduced efficacy of a paclitaxel-doxorubicin chemotherapy combination. We suggest that the poor response rate associated with HER2 expression in advanced breast cancer may not be reversed by aggressive chemotherapy alone.
Collapse
Affiliation(s)
- R Colomer
- Medical Oncology Division, Hospital 12 de Octubre, Madrid, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Colomer R, Llombart A, Lluch A, Ojeda B, Barnadas A, Carañana V, Fernández Y, De Paz L, Guillem V, Alonso S. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Semin Oncol 2000; 27:20-4. [PMID: 10697032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
The purpose of this study was to evaluate the toxicity and efficacy of paclitaxel/gemcitabine administered every 2 weeks in the first-line treatment of advanced breast cancer. Forty-three chemonaive patients with histologically confirmed metastatic breast carcinoma were enrolled. Patients received paclitaxel 150 mg/m2 followed by gemcitabine 2,500 mg/m2, both on day I of a 14-day cycle, for a maximum of eight cycles. Thirty-four patients were evaluable for toxicity; 38 were evaluable for efficacy. The median age at the time of diagnosis was 54 years, the median performance status was 90, and the median number of lesions was three. Most patients (71%) had received prior adjuvant therapy. Grade 3 and 4 toxicity was limited to leukocytes (14% and 18%, respectively). Grade 3 toxicities (5% each) were thrombocytopenia, nausea and vomiting, elevation of aspartate transaminase, neurosensory, and constipation. One patient had neutropenia and fever. The objective response rate was 68% (21% complete response and 47% partial response); 18% had stable disease and 13% had partial disease. The preliminary evaluation of paclitaxel/gemcitabine given as a 2-week schedule to patients with untreated advanced breast carcinoma shows encouraging activity and a favorable toxicity profile.
Collapse
Affiliation(s)
- R Colomer
- Servicio De Oncologia Medica, Hospital 12 de Octubre, Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Salazar R, Solá C, Maroto P, Tabernero JM, Brunet J, Verger G, Valentí V, Cancelas JA, Ojeda B, Mendoza L, Rodríguez M, Montesinos J, López-López JJ. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23:27-33. [PMID: 10037047 DOI: 10.1038/sj.bmt.1701520] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC. They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery. Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively. Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of >0.5 x 10(9)/l and a platelet count of >20 x 10(9)/l were 9 and 11 days. Severe neutropenia (<0.1 x 10(9)/l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred. Gram-positive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis. Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one. The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia.
Collapse
Affiliation(s)
- R Salazar
- Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Sandweiss DH, McInnis H, Burger RL, Cano A, Ojeda B, Paredes R, Sandweiss MC, Glascock MD. Quebrada jaguay: early south american maritime adaptations. Science 1998; 281:1830-2. [PMID: 9743490 DOI: 10.1126/science.281.5384.1830] [Citation(s) in RCA: 196] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Excavations at Quebrada Jaguay 280 (QJ-280) (16 degrees30'S) in south coastal Peru demonstrated that Paleoindian-age people of the Terminal Pleistocene (about 11,100 to 10,000 carbon-14 years before the present or about 13,000 to 11,000 calibrated years before the present) in South America relied on marine resources while resident on the coast, which extends the South American record of maritime exploitation by a millennium. This site supports recent evidence that Paleoindian-age people had diverse subsistence systems. The presence of obsidian at QJ-280 shows that the inhabitants had contact with the adjacent Andean highlands during the Terminal Pleistocene.
Collapse
Affiliation(s)
- DH Sandweiss
- D. H. Sandweiss, Department of Anthropology, South Stevens Hall, University of Maine, Orono, ME 04469, USA. H. McInnis, Institute for Quaternary Studies, Bryand Hall, University of Maine, Orono, ME 04469, USA. R. L. Burger, Peabody Museum of Na
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer. Semin Oncol 1997; 24:S15-40-S15-43. [PMID: 9346221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
This phase II trial was planned to study the efficacy and toxicity of a fixed dose of cisplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given over 1 hour with intrapatient dose escalation. Patients with advanced epithelial ovarian cancer (stages IIB-IV); Eastern Cooperative Oncology Group performance status < or = 2; normal renal, liver, and bone marrow function; and evaluable residual disease after debulking surgery were accrued. Paclitaxel was given over 1-hour infusion and dose was escalated from 175 to 200 and 225 mg/m2 if nadir neutrophil counts were > or = 1000/microL, platelets were > or = 100,000/microL, and neurotoxicity was less than grade 2. Cisplatin was given after paclitaxel at a fixed dose of 80 mg/m2. Six courses at 3-week intervals were planned. From May 1995 to August 1996, 68 patients were entered. Paclitaxel could not be escalated in six patients, another six received up to 200 mg/m2, and 45 received 225 mg/m2. Three hundred seventy-five courses were given: 27.7% at 175 mg/m2, 19.2% at 200 mg/m2, and 53.1% at 225 mg/m2. All patients were evaluable for toxicity, and 67 were evaluable for response. Thirty-five patients had a complete clinical response (51.4%), 20 had a partial response (29.4%), six had stable disease (8.9%), and six progressed on therapy (8.9%). Overall response rate was 80.8 (95% confidence interval, 71.3% to 90.1%). Second-look laparotomy was performed in 32 patients, and 20 of them (62.5%) had a pathologic complete remission. Grade 3 or 4 neutropenia was seen in 26 patients (38%), but only one had fever. Severe thrombocytopenia was not seen. Peripheral neurotoxicity (grade 1, 39.7%; grade 2, 42.6%; and grade 3, 8.8%) was dose-limiting. It is too early to report on time to progression and survival, and these data are not yet available. This combination of cisplatin with escalating doses of paclitaxel is feasible and very active, but the high incidence of peripheral neurotoxicity may limit its use.
Collapse
Affiliation(s)
- A Cervantes
- Hospital Clínico Universitario, Valencia, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Martin M, Lluch A, Ojeda B, Barnabas A, Colomer R, Massuti B, Benito D. Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity. Semin Oncol 1997; 24:S17-26-S17-30. [PMID: 9374088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
This ongoing phase II trial was designed to determine the antitumor activity and cardiotoxicity of a combination of doxorubicin (50 mg/m2) and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (175 to 225 mg/m2 over 3 hours) as first-line chemotherapy for metastatic breast cancer. Of 76 patients entered so far, 57 who had received at least three courses of chemotherapy are assessable for efficacy and cardiac toxicity. A slight majority (57%) of the patients entered had prior adjuvant chemotherapy, including 33% with anthracycline-containing combinations. An objective response was achieved by 70% of patients, with 18% complete responders. The main noncardiac toxicities were alopecia, neutropenia, mucositis, and peripheral neuropathy. Overall, after a median cumulative doxorubicin dose of 350 mg/m2, the evolution of left ventricular ejection fraction (LVEF) values did not significantly decrease from baseline to the sixth course of therapy. However, LVEF values decreased significantly in eight patients (14%). The LVEF decreased by more than 14% over basal values in three patients, although the final determination was still above the lower limits of normal. The remaining five patients had LVEF decreases that fell below the lower limits of normal (33% to 48%). None of the patients developed clinically evident heart failure. Our results indicate that the combination of doxorubicin (50 mg/m2) plus paclitaxel (175 to 225 mg/m2) is effective and does not induce a clinically relevant cardiotoxicity.
Collapse
Affiliation(s)
- M Martin
- Hospital Universitario San Carlos, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
43
|
Sola C, Salazar R, Maroto P, Tabernero J, Valentí V, Brunet J, Ojeda B, Alonso M, Verger G, López López J. Analysis of pulmonary infections during high-dose chemotherapy (HDC) and peripheral blood stem cell autologous transplantation (PBSCT). Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)84871-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
44
|
Maroto P, Solo C, Salazar R, Cancelas J, Brunet J, Tabernero J, Alonso M, Ojeda B, Garcia J, López J. Prospective analysis of factors affecting CD34+ cells mobilization in breast cancer patients. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)84854-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Sola C, Ojeda B, Brunet J, López López JJ. [High-dosage chemotherapy in breast cancer]. Med Clin (Barc) 1997; 108:398-9. [PMID: 9139151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
46
|
Navarro MA, Mesía R, Díez-Gibert O, Rueda A, Ojeda B, Alonso MC. Epidermal growth factor in plasma and saliva of patients with active breast cancer and breast cancer patients in follow-up compared with healthy women. Breast Cancer Res Treat 1997; 42:83-6. [PMID: 9116322 DOI: 10.1023/a:1005755928831] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
We measure EGF in saliva and plasma from 52 patients with active breast cancer, 22 breast cancer patients in follow-up (non-active) and 33 healthy women. EGF concentrations in saliva were significantly higher in patients with active and non-active breast cancer than healthy women, whereas the opposite results were found in plasma. The highest values of EGF in saliva were found in the local recurrence subgroup.
Collapse
Affiliation(s)
- M A Navarro
- Hormone Unit, Hospital Prínceps d'Espanya, Ciutat Sanitària i Universitària de Bellvitge
| | | | | | | | | | | |
Collapse
|
47
|
Abstract
Breast cancer in the elderly has attracted considerable interest in recent years for three main reasons. Firstly, information concerning the profile (clinical and biological) of the disease in the geriatric population is scarce; secondly, the number of patients is increasing, and thirdly there are conflicting data regarding the actual effectiveness of the different treatments. The present review attempts to outline the specific characteristics of this malignancy in the elderly in terms of histological pattern, stage at diagnosis, and outcome. The feasibility of standard therapies (mastectomy/lumpectomy, axillary clearance, and radio-therapy) in the elderly is carefully analysed, and compared to the efficacy of less aggressive procedures. The use of tamoxifen as a primary treatment, instead of surgery, is critically reconsidered, as well as its use as an adjuvant therapy. Finally, the effectiveness of systemic therapy in advanced disease is also discussed.
Collapse
Affiliation(s)
- M Bellet
- Department of Medical Oncology, Hospital Sta Creu i Sant Pau, Barcelona, Spain
| | | | | |
Collapse
|
48
|
Sola Rocabert C, Mesía R, Mendoza L, Tabernero JM, Amill B, Maroto P, Bellet M, Ojeda B, Alonso MC, Verger G. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means]. Med Clin (Barc) 1995; 105:407-11. [PMID: 7475451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BACKGROUND In the last years high dose chemotherapy (HDC) schedules have been developed with autologous bone marrow transplantation (ABMT) which are very effective in breast cancer. Expectation has been raised concerning the cure of a subgroup of patients with metastatic breast cancer and the improvement of prognosis in high risk stages II and III. METHODS CTCb (cyclophosphamide 6 g/m2, thiotepa 500 mg/m2 and carboplatin 800 mg/m2) was administered with autologous peripheral hematopoietic progenitor cells transplantation (TACPHP) and granulocytic colony stimulating factor (G-CSF) 5 micrograms/kg/day to 27 patients with breast cancer: 9 in stage IV in complete remission, 12 in stage II with > or = 10 affected lymph nodes and 6 in stage III. RESULTS No toxic deaths were reported. The median time to achieve > or = 0.5 x 10(9) neutrophils/l was 8 days, to > or = 20 x 10(9) platelets/l 9 days and to > or = 50 x 10(9) platelets/l 12 days. Fever was observed in 85% of the patients although its median duration was of only one day. Extrahematologic toxicity was moderate with grade III nausea/vomiting in 48% of patients, grade III mucositis in 22%, grade III hepatitis in 19%, and grade III diarrhea in 4%. No grade IV toxicity was observed. The median follow-up is still short (10 months, range: 2-25). All the patients maintain normal hematologic peripheral blood counts and only 4 (in stage IV) have relapsed. CONCLUSIONS The slight extrahematologic toxicity observed in the high dose chemotherapy with cyclophosphamide, thiotepa and carboplatin, and the rapid hematologic recovery provided by the TACPHP and G-CSF allow the above schedule to be administered with moderate toxicity and no mortality. This low toxic profile leads to the possibility of future trials with this chemotherapy schedule in other subgroups of patients with breast cancer.
Collapse
Affiliation(s)
- C Sola Rocabert
- Departamento de Oncología, Hospital de la Santa Creu i Sant Pau, Barcelona
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Alonso MC, Tabernero JM, Ojeda B, Llanos M, Solà C, Climent MA, Seguí MA, López JJ. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Breast Cancer Res Treat 1995; 34:15-24. [PMID: 7749156 DOI: 10.1007/bf00666487] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
One hundred patients with metastatic breast cancer were randomly selected to receive combined chemotherapy treatment with adriamycin (50 mg/m2) or mitoxantrone (12 mg/m2) associated with 5-fluorouracil (600 mg/m2) and cyclophosphamide (600 mg/m2) administered intravenously every 21 days with a maximum of ten cycles. All patients included in this study were under 75 years of age and had ECOG performance status of less than 4. They had not been treated previously with chemotherapy for metastatic disease. Patients treated with adjuvant chemotherapy, which could not have included anthracyclines, had to have relapsed at least 12 months after the completion of therapy. There were no statistically significant differences in pretreatment characteristics or metastatic disease location between the two groups. Ninety-four patients were assessable for response. No differences were observed in response rate or in survival between the groups. The response rate (complete response (CR) and partial response (PR)) was 68% (13% CR and 55% PR for CAF; 0% CR and 68% PR for CNF). Median survival for all patients was 19 months (18 months with CAF and 19 months with CNF). All patients were assessable for toxicity. There were no differences in gastrointestinal and cardiac toxicity. More grade I-II hematologic toxicity episodes (p < 0.001) and treatment delays (p = 0.05) due to leucopenia were observed with the CNF group, and more grade III alopecia (p < 0.001) was observed with the CAF group. Patients received further therapeutic manoeuvres after finishing the study with a sequential treatment consisting of hormonal therapy and chemotherapy with mitomycin (M) -vinblastine (Vbl) (M 10 mg/m2 day 1, Vbl 5 mg/m2 days 1, 15 and 29; maximum 5 cycles). This chemotherapy treatment was received by 32 patients, with a response rate of 34% and grade III-IV hematologic toxicity of 37%. Treatment with CNF can be considered a good alternative to CAF for first-line treatment of metastatic breast cancer. M-Vbl treatment is useful as second-line treatment in patients with prior adriamycin exposure.
Collapse
Affiliation(s)
- M C Alonso
- Medical Oncology Department, Universitat Autònoma de Barcelona, Hospital de Sant Pau, Spain
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Ojeda B, Llanos M, Brunet J, Lacasta A, Alonso MC, Rueda A, Delgado E, Badía J, López López JJ. [10 Year follow up of chemotherapy and surgery on the second laparotomy in advanced ovarian cancer]. Med Clin (Barc) 1995; 104:165-9. [PMID: 7877374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
BACKGROUND Advanced ovarian neoplasm has bad prognosis. There is little knowledge as to the effect of surgical and chemotherapy treatments on long-term survival. METHODS Seventy-two patients with advanced epithelial ovary carcinoma (53 stage III and 19 stage IV) were treated according to a treatment regimen with reduction surgery, five cycles of chemotherapy with cyclophosphamide, adriamycin and cisplatin (CAP) followed by second revision laparotomy. RESULTS The rate of response for the CAP schedule was 80%, of which 16 patients (23%) showed complete response (CR), 7 (10%) partial microscopic response (PMiR) and 33 (47%) partial macroscopic response (PMR). Complete resection of residual masses was performed on the second laparotomy in 14 of the 33 patients with parital response. The median survival for all the group was 36 months with overall actuarial survival of 27% at 10 years. The survival of the group of patients with CR was significantly longer than that of PMiR and other groups. Significant differences favorable for the group of partial response with second attempt radical surgery were found versus the group in which te second surgical resection was not radical. FIGO III stage and prechemotherapy tumor size less than 5 cm were found to have favorable effect in the rate of response and survival. CONCLUSIONS The use of CAP chemotherapy achieved complete response in 23% of the patients studied. This group of patients showed to have a greater probability of longer survival. Second attempt surgery on the second laparotomy offers therapeutic benefits when radical.
Collapse
Affiliation(s)
- B Ojeda
- Servicio de Oncología, Hospital de la Santa Creu i Sant Pau, Barcelona
| | | | | | | | | | | | | | | | | |
Collapse
|